Table 2

Clinical responses to lixisenatide (LIXI) or placebo (PBO) add-on treatment to basal insulin therapy±oral antidiabetic drugs in the overall pooled population and by baseline body mass index (BMI) subgroup

BMI <25 kg/m2BMI 25–<30 kg/m2BMI ≥30 kg/m2All pooled participantsInteraction
P value
PBO
(n=79)
LIXI
(n=104)
PBO
(n=142)
LIXI
(n=134)
PBO
(n=42)
LIXI
(n=54)
PBO
(n=263)
LIXI
(n=291)
HbA1c, %
 Mean±SD at baseline7.89±0.678.00±0.737.97±0.728.01±0.788.10±0.847.97±0.777.97±0.738.00±0.760.345
 Mean±SD at week 248.08±1.207.57±1.097.88±0.987.57±1.288.21±1.247.46±1.217.99±1.107.55±1.20
 LSM±SE change from baseline0.29±0.14–0.33±0.13–0.11±0.12–0.53±0.11–0.04±0.19–0.61±0.170.02±0.08–0.49±0.08
 LSM difference (95% CI)–0.62 (–0.93 to –0.31)–0.42 (–0.67 to –0.17)–0.58 (–1.02 to –0.13)–0.51 (–0.68 to –0.33)
 P value<0.0010.0010.013<0.001
HbA1c <7% at week 24, n (%)9 (11.4)34 (33.3)21 (15.0)42 (33.1)4 (9.5)18 (34.0)34 (13.0)94 (33.3)0.852
 Risk difference (SE)21.9 (5.9)18.1 (5.2)24.4 (7.9)20.3 (3.5)
 OR (95% CI)5.98 (2.24 to 15.97)4.18 (2.08 to 8.37)4.71 (1.20 to 18.51)4.35 (2.66 to 7.12)
 P value<0.001<0.0010.027<0.001
FPG, mmol/L
 Mean±SD at baseline6.81±1.817.12±2.316.71±1.837.17±2.257.14±2.096.80±1.706.81±1.867.08±2.180.156
 Mean±SD at week 247.49±2.237.19±2.137.31±2.237.63±2.828.60±2.557.14±2.457.57±2.327.38±2.52
 LSM±SE change from baseline0.45±0.300.06±0.270.57±0.260.48±0.251.09±0.42–0.12±0.380.58±0.170.23±0.16
 LSM difference (95% CI)–0.39 (–1.03 to 0.25)–0.10 (–0.65 to 0.46)–1.21 (–2.21 to –0.21)–0.34 (–0.72 to 0.03)
 P value0.2340.7310.0190.074
2-hour PPG, mmol/L
 Mean±SD at baseline14.02±3.5114.79±5.0114.17±3.9213.90±4.1913.82±3.6112.68±3.8714.07±3.7413.99±4.490.180
 Mean±SD at week 2414.84±4.3410.58±5.1613.8±3.9510.76±4.4813.94±3.7910.22±5.4614.14±4.0610.60±4.90
 LSM±SE change from baseline–0.42±0.67–4.63±0.62–1.07±0.49–4.20±0.490.04±0.95–3.34±0.83–0.59±0.36–4.11±0.34
 LSM difference (95% CI)–4.21 (–5.71 to –2.71)–3.13 (–4.18 to –2.08)–3.38 (–5.66 to –1.11)–3.52 (–4.31 to –2.73)
 P value<0.001<0.0010.004<0.001
2-hour PPG excursion, mmol/L
 Mean±SD at baseline7.29±3.647.62±4.107.27±3.246.72±3.346.44±2.675.52±3.537.15±3.296.81±3.720.162
 Mean±SD at week 247.43±3.893.60±5.006.63±3.463.39±4.045.45±3.453.14±4.146.70±3.643.42±4.40
 LSM±SE change from baseline–0.88±0.63–4.46±0.59–1.45±0.45–4.48±0.45–0.97±0.78–2.95±0.67–1.04±0.33–4.13±0.31
 LSM difference (95% CI)–3.58 (–4.98 to –2.18)–3.03 (–3.99 to –2.08)–1.98 (–3.83 to –0.13)–3.09 (–3.81 to –2.38)
 P value<0.001<0.0010.036<0.001
Body weight, kg
 Mean±SD at baseline62.00±7.4161.76±7.3372.88±9.9273.63±9.6989.39±10.4985.57±11.7772.28±12.8971.60±12.670.726
 Mean±SD at week 2462.62±7.7061.41±7.6973.09±10.6572.64±9.9189.36±10.2584.64±11.8372.58±13.0770.85±12.67
 LSM±SE change from baseline0.63±0.25–0.28±0.230.35±0.28–0.78±0.270.25±0.48–0.71±0.440.39±0.18–0.61±0.17
 LSM difference (95% CI)–0.92 (–1.44 to –0.39)–1.14 (–1.71 to –0.56)–0.96 (–2.12 to 0.19)–1.00 (–1.38 to –0.62)
 P value<0.001<0.0010.100<0.001
BMI, kg/m2
 Mean±SD at baseline23.07±1.2423.22±1.3127.36±1.4627.13±1.4033.38±2.5332.91±2.5427.05±3.7326.80±3.790.779
 Mean±SD at week 2423.29±1.3123.07±1.4027.43±1.7126.77±1.6133.39±2.6032.56±2.8527.15±3.7426.52±3.81
 LSM±SE change from baseline0.22±0.09–0.12±0.080.05±0.10–0.36±0.100.13±0.19–0.24±0.170.12±0.07–0.25±0.06
 LSM difference (95% CI)–0.34 (–0.54 to –0.15)–0.41 (–0.63 to –0.20)–0.37 (–0.81 to 0.07)–0.37 (–0.51 to –0.23)
 P value<0.001<0.0010.101<0.001
  • FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LSM, least squares mean; PPG, postprandial glucose.